Jeffrey V. Lazarus Receives the 2023 Distinguished Scientific Achievement Award from the American Liver Foundation

ISGlobal researcher Jeffrey V. Lazarus has been awarded the 2023 Distinguished Scientific Achievement Award by the American Liver Foundation. Lazarus, who is also Associate Professor at the University of Barcelona and Professor of Global Health at the CUNY Graduate School of Public Health and Health Policy, was recognised for his significant impact in areas such as viral hepatitis, metabolic dysfunction associated steatotic liver disease (MASLD) and global health. The award ceremony took place on 13 November in Boston, USA.

Expert in health systems, viral hepatitis and HIV

The recognition is based on Lazarus' more than 25 years of experience in health systems and policy, and his research on diseases such as viral hepatitis, HIV and, more recently, COVID-19. His focus is on expanding access to care within health systems, particularly person-centred care and improving quality of life. He has worked to improve outcomes for global infectious and stigmatised diseases, and to form collaborative, multidisciplinary teams to generate knowledge applicable to diverse areas of disease and systemic risk.

"I dedicate this award to my team and my hundreds of co-authors of numerous global consensus statements, policy reviews, guidelines, studies and real-world fieldwork.” Lazarus said. “Together, we have expanded the practice community and improved policy. What's next? Saving even more lives.

A life dedicated to liver disease

 Jeffrey V. Lazarus has had a distinguished career with the World Health Organization (WHO) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. He has held key positions in the European Association for the Study of the Liver (EASL) and currently coordinates the “Healthy Livers, Healthy Lives” coalition formed in 2022 by leading liver organisations (AASLD, ALEH, APASL and EASL). He is the author of 400 publications, including the landmark NAFLD public health consensus statement, the new steatotic liver disease (formerly known as fatty liver disease) nomenclature, and the global research and action priorities to set the first global action plan for the field of steatotic liver disease.